Key result
Bioresorbable scaffolds provide marginal QALE benefit over EES emerging only after ~22 years.
Why the study?
Poly-L-lactic acid-based bioresorbable scaffolds are associated with increased 3-year device thrombosis versus metallic everolimus-eluting stents, but their long-term performance remains unknown.
Does the use of bioresorbable scaffolds compared to everolimus-eluting stents improve quality-adjusted life expectancy in patients undergoing percutaneous coronary interventions?
Does the use of bioresorbable scaffolds compared to everolimus-eluting stents improve quality-adjusted life expectancy in patients undergoing percutaneous coronary interventions?
Current bioresorbable scaffolds require approximately 21.8 years to overcome early thrombosis hazards and provide a net quality-adjusted life expectancy benefit compared to everolimus-eluting stents.
Answers are grounded in this paper and cite their sources.
Negligible modeled QALE gain emerges only after 22 years; leaves open whether bioresorbable scaffolds merit further randomized evaluation.
OBJECTIVE: Use of poly-L-lactic acid-based bioresorbable scaffolds (BRS) has been associated with increased risk of device thrombosis during the first 3 years after implantation as compared to metallic everolimus-eluting stents (EES). The long-term performance of BRS relative to EES remains unknown. METHODS: We used a Markov decision analysis model to evaluate the effectiveness of BRS vs. EES over a lifetime horizon. In addition to one-way sensitivity analyses of key variables, we evaluated the impact of optimal implantation technique and limiting procedures to larger vessels (>2.6 mm in diameter) on model results. RESULTS: Assuming no risk of target lesion revascularization for BRS after 3 years, we found a small increment in quality-adjusted life expectancy (QALE) of 0.02 with the use of BRS relative to EES, with benefit being observed after 21.8 years. Optimal implantation technique and limiting to larger vessels resulted in larger gains in QALE (0.08 and 0.06, respectively) with BRS and shorter times to equipoise (6.7 and 8.3 years, respectively). Model results were highly sensitive to variations in the relative risk of stent thrombosis (BRS vs. EES). CONCLUSIONS: Based on currently available data, it would take approximately 21.8 years for the presumed late benefits of current BRS relative to EES to overcome the early hazard associated with their use under favorable assumptions. Optimal implantation technique and limiting procedures to larger vessels improved BRS performance and reduced time to equipoise. Eliminating the higher BRS thrombosis risk is necessary in developing future generations of BRS as an acceptable alternative to EES.
No takes yet. Share an insight, caveat, or question.
Fazel et al. (2019) studied Percutaneous coronary interventions. Poly-L-lactic acid-based bioresorbable scaffolds (BRS) vs. Metallic everolimus-eluting stents (EES) was evaluated on Quality-adjusted life expectancy (QALE) (increment of 0.02). Bioresorbable scaffolds provided a small increment in quality-adjusted life expectancy of 0.02 relative to everolimus-eluting stents, with the benefit being observed after 21.8 years.
Synapse has enriched 10 related papers. Consider them for comparative context: